<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837404</url>
  </required_header>
  <id_info>
    <org_study_id>9343</org_study_id>
    <nct_id>NCT04837404</nct_id>
  </id_info>
  <brief_title>Ultrasound Guided Transfemoral Complex Large-bore PCI Trial</brief_title>
  <acronym>ULTRACOLOR</acronym>
  <official_title>Ultrasound Guided Transfemoral Complex Large-bore PCI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maatschap Cardiologie Zwolle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diagram B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maatschap Cardiologie Zwolle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ULTRACOLOR is a randomized multicentre investigator-initiated study to investigate if&#xD;
      ultrasound guided femoral access is associated with less clinically relevant access site&#xD;
      related bleeding and/or vascular complications requiring intervention as compared to the&#xD;
      fluoroscopy guided method for complex PCI with large-bore access.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ULTRACOLOR is a prospective, multicentre, randomized investigator-initiated trial designed to&#xD;
      enroll 542 subjects with an indication for PCI for complex coronary lesions.&#xD;
&#xD;
      This study will investigate if ultrasound guided femoral access is associated with less&#xD;
      clinically relevant access site related bleeding and/or vascular complications requiring&#xD;
      intervention as compared to the fluoroscopy guided method for complex PCI with large-bore&#xD;
      access.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multicentre, randomized investigator-initiated trial with a superiority design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with BARC 2, 3 or 5 access-site related bleeding or vascular complication requiring intervention of the primary femoral access site during index hospitalization.</measure>
    <time_frame>up to discharge hospital, on average 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with BARC 2, 3 or 5 access-site related bleeding or vascular complication requiring intervention of the secondary femoral or radial access site during index hospitalization.</measure>
    <time_frame>up to discharge hospital, on average 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with BARC 2, 3 or 5 access-site related bleeding or vascular complication requiring intervention of the primary femoral access site at 1 month.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with BARC 2, 3 or 5 access-site related bleeding or vascular complication requiring intervention of the secondary femoral or radial access site at 1 month</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with MACE</measure>
    <time_frame>up to discharge hospital (on average 24 hours) and at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural duration</measure>
    <time_frame>during PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of first pass puncture</measure>
    <time_frame>during PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of access attempts</measure>
    <time_frame>during PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of.accidental venipuncture</measure>
    <time_frame>during PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of access below the femoral artery bifurcation (ileofemoral angiogram)</measure>
    <time_frame>during PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vascular complication not requiring intervention of the primary femoral access site</measure>
    <time_frame>up to discharge hospital (on average 24 hours) and at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vascular complication not requiring intervention of the secondary femoral or radial access site</measure>
    <time_frame>up to discharge hospital (on average 24 hours) and at 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">542</enrollment>
  <condition>Complex Coronary Lesions</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>ultrasound guided femoral access</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Ultrasound guided femoral access will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluoroscopy guided femoral access</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Fluoroscopy guided femoral access will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound guided femoral access for complex PCI</intervention_name>
    <description>Ultrasound guided femoral access for complex PCI</description>
    <arm_group_label>ultrasound guided femoral access</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluoroscopy guided femoral access for complex PCI</intervention_name>
    <description>Fluoroscopy guided femoral access for complex PCI</description>
    <arm_group_label>fluoroscopy guided femoral access</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Use of the femoral artery for primary or secondary access with â‰¥ 7 Fr guiding catheter&#xD;
             as indication for complex PCI, according to the expertise of the treating physician.&#xD;
&#xD;
          2. Age 18 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to obtain informed consent&#xD;
&#xD;
          2. Contra-indication for femoral access&#xD;
&#xD;
          3. Cardiogenic shock&#xD;
&#xD;
          4. ST elevation myocardial infarction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maarten van Leeuwen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jolanda Pol-van der Velde, MSc</last_name>
    <phone>+31 (0)38 426 2999</phone>
    <email>jo.pol@diagram-zwolle.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Isala Hospital</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maarten van Leeuwen, MD, PhD</last_name>
      <phone>+31 38 424 50 00</phone>
      <email>m.a.h.van.leeuwen@isala.nl</email>
    </contact>
    <investigator>
      <last_name>Maarten van Leeuwen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Meijers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

